AzTrials
AzTrials

Anal Squamous Cell CarcinomaPhase 2REFIT-MSSNCT05582031

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

A Phase 2 study testing Regorafenib in combination with Tislelizumab in people with Anal Squamous Cell Carcinoma and Colorectal Neoplasms, run by Translational Research in Oncology.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

REFIT-MSS is a non-randomized, multicenter, open-label, multi-cohort, 2-stage, phase II trial to evaluate the efficacy and safety of regorafenib in combination with tislelizumab (referred as Rego-Tisle) in adult patients with select advance, previously treated, Mismatch Repair-Proficient/Microsatellite (pMMR/MSS)… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Regorafenib in combination with Tislelizumab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
No sites listed yet
Study dates
30 Apr 2023to 30 Apr 2025
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Signed and dated PICF obtained prior to any trial-specific procedure that is not part of standard patient care.
  • Patient is ≥ 18 years-old at the time of PICF signature (or the legal age of consent in the jurisdiction in which the trial is taking place).
  • Histologically or cytologically confirmed solid tumor belonging to one of the cohorts specified in the protocol. To be eligible, patient must meet the criteria for tumor type, stage and prior anti-cancer therapy according to the protocol.
  • Tumor must be:
  • In all colorectal (CRC patients) and in any non-CRC patient with dMMR/MSI testing available prior to enrollment: pMMR/MSS tumor based on IHC, MSI-PCR or NGS testing, as performed at the site prior to enrollment according to site's standard practice.
  • In any non-CRC patient with unknown dMMR/MSI status: the site must confirm at screening that the patient has available and retrievable archival tumor tissue from the primary or metastatic site, for submission to a central laboratory for dMMR/MSI testing.
Show all 14Show fewer
  • Measurable disease by CT or MRI per Response Evaluation Criteria in Solid Tumors (version 1.1), based on tumor assessment performed within 28 days of enrollment.
  • Progressive cancer at the time of trial entry based on clinical or radiographic findings or tumor marker evaluation, according to Investigator's judgment, or cancer that is not amenable to standard therapies even if not progressing.
  • ECOG Performance Scale score of 0 or 1 at enrollment.
  • Adequate hematologic and organ function as assessed by the following laboratory tests, performed at screening (specified within the protocol).
  • Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures.
  • Women of childbearing potential (CBP) must have confirmed negative serum pregnancy test (for β-hCG) within 7 days prior to enrollment.
  • Women of CBP must agree to remain completely abstinent (complete avoidance of heterosexual intercourse) or use highly effective contraceptive methods (i.e., with a failure rate of < 1% per year) during the Treatment Phase and for at least 7 months after the last trial treatment intervention.
  • Men who are sexually active with women of CBP must agree to remain completely abstinent (complete avoidance of heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm during the Treatment Phase and for a total of 7 months post-treatment completion.

Who cannot join

  • Prior treatment with regorafenib.
  • Prior treatment with a PD1, PD-L1/PD-L2, or CTLA-4 inhibitor, or any other drug or antibody targeting T-cell co-stimulation or checkpoint pathways, except in patients that meet all the following criteria:
  • Patient received a PD1, PD-L1/PD-L2, or CTLA-4 inhibitor, or any other drug or antibody targeting T-cell co-stimulation or checkpoint pathways in either:
  • Neoadjuvant and/or adjuvant setting and had no relapse within 12 months of completing immunotherapy
  • Advanced disease setting and had no progression during immunotherapy
  • Patient tolerated immunotherapy and did not need to discontinue treatment due to intolerable toxicity
Show all 31Show fewer
  • Evidence of progressive or symptomatic CNS metastases. Patients with treated CNS metastases are eligible if they meet all the following criteria:
  • Minimal neurologic symptoms
  • Evidence of stable disease (for at least 2 weeks prior to enrollment) or response on a follow-up scan performed after CNS treatment completion
  • Require corticosteroids at a dose ≤ 10 mg daily of prednisone or equivalent
  • Previous treatment with live vaccine within 28 days of planned start of trial drugs (seasonal flu vaccines that do not contain a live virus are permitted).
  • Concurrent participation in another clinical study, unless it is: (a) an observational (noninterventional) study, or (b) the follow-up period of an interventional trial and patient did not receive an investigational agent/device within 28 days before enrollment (or within 5 half-lives of the drug).
  • Major surgical procedure, open biopsy, significant traumatic injury, radiation therapy and/or systemic anti-cancer therapy ≤28 days prior to enrollment. Patients must have recovered adequately from the toxicity and/or complications from these interventions before enrollment. Radiation therapy given with palliative intent is allowable if finalized ≥ 14 days prior to enrollment.
  • Known hypersensitivity to any of the trial drugs or its formulation components.
  • Active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids.
  • Requirement of systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medications ≤ 14 days prior to enrollment.
  • Uncontrolled diabetes or > Grade 1 laboratory test abnormalities in potassium, sodium, or calcium despite standard medical management or ≥ Grade 3 hypoalbuminemia, ≤ 14 days prior to enrollment.
  • Interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, or clinically significant acute lung diseases.
  • Any cardiovascular conditions as listed within the protocol.
  • Infection requiring systemic (oral or i.v.) antibacterial, antifungal or antiviral therapy ≤14 days prior to enrollment.
  • Patient unable to swallow and retain oral medication or has impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the oral trial treatment (e.g., uncontrolled ulcerative diseases, uncontrolled nausea, vomiting or diarrhea, malabsorption syndrome, small bowel resection).
  • Prior allogeneic stem cell transplantation or organ transplantation.
  • Evidence or history of bleeding diathesis or any hemorrhage or bleeding event > NCI CTCAE v5.0 Grade 3 within 4 weeks prior to enrollment.
  • Non-healing wound, ulcer, or bone fracture.
  • Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 2 years before enrollment. Note: patients with prior or concurrent adequately treated, basal or squamous cell skin carcinoma or adequately treated in situ carcinomas are eligible.
  • Patient has known active HBV or HCV.
  • Patient has HIV infection, unless they meet certain criteria (listed within the protocol).
  • Persistent proteinuria of NCI CTCAE v5.0 Grade 3. Urine dipstick result of ≥ 3+ is allowed if protein excretion (estimated by urine protein/creatinine ratio on a random urine sample) is < 3.5 g/24 hours.
  • Unresolved clinically significant toxicity (per Investigator's assessment) greater than NCI CTCAE v5.0 Grade 1 attributed to any prior therapy/procedure, excluding alopecia of any grade and non-painful peripheral neuropathy grade ≤ 2 (according to NCI CTCAE v5.0).
  • Patient has any other concurrent severe and/or uncontrolled medical condition or personal, psychological, geographic or social circumstance, that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol and retention.
  • Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial.

About this study

Official title: An Open-label, Phase II, Multi-cohort, 2-stage Trial to Evaluate the Efficacy and Safety of Regorafenib in Combination With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Pretreated Solid Cancers

REFIT-MSS is a non-randomized, multicenter, open-label, multi-cohort, 2-stage, phase II trial to evaluate the efficacy and safety of regorafenib in combination with tislelizumab (referred as Rego-Tisle) in adult patients with select advance, previously treated, Mismatch Repair-Proficient/Microsatellite (pMMR/MSS) stable solid cancers.

The multi-cohort design will allow for the examination of 8 separate cohorts of different cancers to determine whether further examination may be warranted in the individual indications.

Read the detailed description

This is a non-randomized, multicenter, open-label, multi-cohort, phase II trial to evaluate the efficacy and safety of Rego-Tisle in adult patients with solid tumors that are advanced, pretreated and refractory to standard therapy. Approximately 322 evaluable patients (between 15 and 82 per cohort) in around 65 sites will be enrolled to power the trial efficiently to measure the primary endpoint, Progression Free Survival at 6 months (PFS-6).

Patients should have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors guidelines version 1.1 (RECIST 1.1), an Eastern Cooperative Oncology Group Performance Scale (ECOG PS) 0-1, and adequate organ function.

The trial will include patients who had been diagnosed with a histologically or cytologically confirmed solid tumor belonging to any of the types in the cohorts to be enrolled. To be eligible, patient must meet the criteria for tumor type, stage and prior anti-cancer therapy according to inclusion criteria.

Being tested
Regorafenib in combination with Tislelizumab
Keywords
pMMR, MSS, Advanced solid tumors, MKI, PD-1 inhibitors
Medical subject headings
Anus Neoplasms, Colorectal Neoplasms, Sarcoma, Mesothelioma, Malignant, Small Cell Lung Carcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Regorafenib in combination with TislelizumabCombination product

    Regorafenib 30 mg/tablet + Tislelizumab 100 mg/10 ml vial

Study groups in NCT05582031
Study groupRoleWhat they receive
Regorafenib 90 mg + Tislelizumab 300 mg (Rego-Tisle)ExperimentalThe trial will include 8 cohorts of patients, with each cohort considered as a single-arm; all patients enrolled will be treated with regorafenib at a dose of 90 mg orally once daily, on days 1 to 21 of a 28 cycle in combination with tislelizumab 300 mg intravenously day 1 (of a 28 day cycle).
Receives: Combination Product: Regorafenib in combination with Tislelizumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression Free Survival at 6 months (PFS-6) as per Investigator Assessment

    PFS-6 is defined as the proportion of patients who remained free of PFS event (disease progression or death) at 6 months from the date of enrollment.

    Measured: 6 Months

Secondary outcomes (7)

  1. Overall Response Rate

    Defined as the proportion of patients who have a complete response (CR) or partial response (PR) based on investigator assessment.

    Measured: 24 Months

  2. Disease Control Rate (DCR)

    Defined as the proportion of patients who have CR, PR, or stable disease (SD) according to RECIST 1.1, as per investigator assessment.

    Measured: 24 Months

  3. Duration of Response (DOR)

    Defined as the time (in months) from first documentation of response (PR or CR) to progressive disease (PD) or death, based on investigator assessment or death, in patients who had best overall response of CR or PR.

    Measured: 24 Months

  4. Growth Modulation Index (GMI)

    Defined as as the ratio of time to progression (TTP) with the nth line (TTP(n)) of therapy to the TTP(n)(-1) with the n-1th line.

    Measured: 24 Months

  5. Overall Survival (OS)

    Defined as time from date of enrollment to date of death due to any cause. Median OS, OS at 6 months (OS-6) and OS at 12 months (OS-12) will be evaluated.

    Measured: 12 Months

  6. Time to Prostate Specific Antigen (PSA) Progression

    In metastatic castration-resistant prostate cancer (mCRPC) cohort only; defined as the time from the date of enrollment to the date of PSA progression based on Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria

    Measured: 24 Months

  7. Frequency and Severity of Adverse Events (AEs) and Laboratory Abnormalities

    Frequency and severity of AEs and laboratory abnormalities

    Measured: 24 Months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Oct 2022
  2. Study start30 Apr 2023 (estimated)
  3. Primary completion30 Apr 2025 (estimated)
  4. Study completion30 Apr 2025 (estimated)

Why it stopped: Study never started/ will not proceed.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
The trial will include 8 cohorts of patients. Each cohort is considered as a single-arm activity-estimating sub-study with PFS-6 as the primary endpoint. A strong primary endpoint signal seen in a cohort may allow for expansion of the cohort, independently of the status of the other cohorts. Similarly, a cohort may be opened and/or closed for enrollment independently of others.
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05582031
Sponsor's protocol ID
TRIO042
Acronym
REFIT-MSS
Status last verified
Jun 2023
First submitted
12 Oct 2022
Last updated
7 Jun 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Regorafenib in combination with Tislelizumab in people with Anal Squamous Cell Carcinoma and Colorectal Neoplasms, run by Translational Research in Oncology.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 31 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 7 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression Free Survival at 6 months (PFS-6) as per Investigator Assessment (time frame: 6 Months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05582031.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jun 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in